Boston Biomedical - Columbia Collaboration
There are presently no open calls for submissions.
***PLEASE NOTE***: The submission deadline for short proposals has been extended to Wednesday, December 4th, 2019
Columbia University is pleased to announce the 2019 short proposals under the Boston Biomedical - Columbia research collaboration. The collaboration stimulates research and development in the field of oncology through collaborative, Columbia investigator initiated projects.
This Request for Proposals (RFP) is seeking innovative projects toward the discovery and development of novel oncology therapeutics and platform technologies.
Areas of Interest:
Novel therapeutics and platform technologies with a focus on Oncology including (but not limited to):
- Cancer Genomics and Epigenomics
- Tumor biology and microenvironment
- Precision Oncology and Systems Biology
- Cancer Population Science
- Cancer cell metabolism
- Immune-oncology and immunotherapy
- Gene and cell therapy
- DNA vaccines and therapy
- RNAi and oncolytic viruses
- Drug delivery systems
- Gene editing
- Mechanisms of anti-aging therapy
- Imaging and radio-omics
About Boston Biomedical
Boston Biomedical, Inc. is a leading developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. As a fully integrated oncology drug research and development company, Boston Biomedical, Inc. has established a track record of accomplishments, including advancing the research and development of multiple compounds and clinical programs. The company’s range of expertise includes drug discovery, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, CMC (chemistry, manufacturing, and control), global clinical trials, regulatory affairs and commercialization. Headquartered in Cambridge, Massachusetts, Boston Biomedical, Inc. is wholly owned by Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan.